Improving the immunogenicity of E. coli FimH via multivalent display on I53-50 nanoparticles - Takeaways - MDSpire

Enhancing the Immunogenic Response of E. coli FimH through Multivalent Presentation on I53-50 Nanoparticles

  • By

  • Rebecca S. Cole

  • Natalie C. Silmon de Monerri

  • Jacqueline Lypowy

  • Christopher Ponce

  • Cara Kobylarz

  • Lily Liu

  • Zein Kasbo

  • Elizabeth Kepl

  • Tara Ciolino

  • Art Illenberger

  • Leslie Gallardo

  • Annalena Laporte

  • Danielle Baranova

  • Rashmi Ravichandran

  • Laurent O. Chorro

  • Robert G.K. Donald

  • Raphael Simon

  • Neil P. King

  • July 21, 2026

Share

  • 1

    Urinary tract infections, primarily caused by uropathogenic E. coli, affect approximately 50% of women globally.

  • 2

    FimH, an adhesin responsible for host receptor binding, is a promising vaccine candidate but is poorly immunogenic in its monomeric form.

  • 3

    Nanoparticle immunogens displaying FimH antigens on I53-50 elicited robust receptor-blocking antibodies in mice and non-human primates.

  • 4

    Both FimHLD and FimH-DSG displayed on I53-50 induced similar receptor-blocking activity as a higher dose of monomeric FimH-DSG with adjuvant.

  • 5

    The study demonstrates the potential of the I53-50 nanoparticle platform for enhancing the immunogenicity of bacterial antigens.

Original Source(s)

Related Content